Bristol-Myers Squibb vs Volkswagen: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. Volkswagen was founded in 1937 by Ferdinand Porsche and is led by Oliver Blume.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
Volkswagen
- Founded
- 1937
- Headquarters
- Wolfsburg, Germany
- Current CEO
- Oliver Blume
- Employees
- 663,000
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
Volkswagen
Ferdinand Porsche
Ferdinand Porsche (1875-1951) was an Austrian-born automotive engineer who had worked for Lohner, Austro-Daimler and Daimler-Benz before opening his own design office in Stuttgart in 1931.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
Volkswagen
- Hermann Münch1946–1947
Chief Executive Officer
Early executive involved in the incredibly complex immediate post-war administration of the completely destroyed factory under British military control.
Source - Heinrich Nordhoff1948–1968
Chief Executive Officer
The absolute legendary post-war architect who took the ruins of the VW factory and transformed the Beetle into a massive, globally beloved cultural icon and economic miracle.
Source - Kurt Lotz1968–1971
Chief Executive Officer
Early post-war leader who began the critical process of diversifying VW's lineup beyond relying entirely on a single model (the Beetle).
Source - Rudolf Leiding1971–1975
Chief Executive Officer
Crucial CEO who managed the extremely difficult, highly risky transition away from the iconic but severely outdated Beetle toward modern, front-wheel-drive water-cooled cars (like the Golf).
Source - Toni Schmücker1975–1982
Chief Executive Officer
Guided the company through the severe financial crises of the 1970s, ensuring the successful launch and massive adoption of the original VW Golf.
Source - Carl Hahn1982–1993
Chief Executive Officer
As CEO in the 1980s, he executed the massive, highly strategic acquisitions of SEAT and Skoda, laying the foundation for VW's absolute dominance in Europe.
Source - Ferdinand Piëch1993–2002
Chief Executive Officer
As the legendary, absolutely ruthless patriarch (and grandson of Ferdinand Porsche), he transformed VW from a struggling mass-market brand into the most powerful automotive conglomerate on Earth.
Source - Bernd Pischetsrieder2002–2006
Chief Executive Officer
Serving as CEO from 2002 to 2006, he oversaw the incredibly complex integration of massive luxury brands like Bugatti and Bentley into the VW Group portfolio.
Source - Martin Winterkorn2007–2015
Chief Executive Officer
As the notoriously demanding, absolutely feared CEO, he oversaw massive global expansion but fostered a culture of absolute terror that led engineers to cheat rather than admit failure.
Source - Matthias Müller2015–2018
Chief Executive Officer
As CEO during the darkest period in modern VW history, he initiated the massive cultural purge of the toxic, highly secretive engineering culture that caused the cheating scandal.
Source - Herbert Diess2018–2022
Chief Executive Officer
Serving as CEO, he forcefully dragged the massive, highly bureaucratic legacy automaker into the Tesla era, though his abrasive style alienated the powerful Porsche-Piëch families.
Source - Oliver Blume2022–present
Chairman of the Board of Management
He also ran Porsche AG alongside the group role until Michael Leiters took over as Porsche CEO on January 1, 2026, leaving Blume focused on Volkswagen Group.
Source
Timeline: Bristol-Myers Squibb and Volkswagen side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1937Volkswagen
Volkswagen founded
Volkswagen was founded under the German Labour Front as part of a state-directed people's car program.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1945Volkswagen
Wolfsburg restarted
British military administration helped restart peacetime production at Wolfsburg after World War II.
1965Volkswagen
Audi foundation added
Volkswagen acquired Auto Union from Daimler-Benz, creating the foundation for modern Audi.
1974Volkswagen
Golf production begins
The Golf gave Volkswagen a modern front-engine, front-wheel-drive compact platform after the Beetle era.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2012Volkswagen
Porsche consolidated
Porsche became a controlled sport-luxury profit anchor within Volkswagen Group.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2015Volkswagen
Matthias Müller becomes CEO
Matthias Müller became CEO of Volkswagen Aktiengesellschaft in 2015. Chief executive of Volkswagen Aktiengesellschaft from 2015 to 2018.
2015Volkswagen
Emissions Scandal
US regulators accused Volkswagen in September 2015 of fitting diesel cars with software that cheated emissions tests.
2018Volkswagen
Herbert Diess becomes CEO
Herbert Diess became CEO of Volkswagen Aktiengesellschaft in 2018. Chief executive of Volkswagen Aktiengesellschaft from 2018 to 2022.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2022Volkswagen
Oliver Blume becomes chairman
Oliver Blume became chairman of Volkswagen Aktiengesellschaft in 2022. He also ran Porsche AG alongside the group role until Michael Leiters took over as Porsche CEO on January 1, 2026, leaving Blume focused on Volkswagen Group.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2024Volkswagen
Rivian software joint venture
Volkswagen and Rivian launched a software joint venture targeting next-generation electrical architecture.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2025Volkswagen
Revenue reaches ~$364B (EUR321.9B)
Volkswagen reported ~$364 billion (EUR321.9 billion) in sales revenue, ~$10.1 billion (EUR8.9 billion) in operating result, and 8.984 million deliveries.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
Volkswagen
- Porsche AG2012Undisclosed
- Bentley Motors1998Undisclosed
- Auto Union / Audi1965Undisclosed
Questions about Bristol-Myers Squibb vs Volkswagen
Who is the CEO of Bristol-Myers Squibb Company and Volkswagen Aktiengesellschaft?
Bristol-Myers Squibb Company is led by Christopher Boerner and Volkswagen Aktiengesellschaft is led by Oliver Blume. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Volkswagen Aktiengesellschaft?
Bristol-Myers Squibb Company was founded in 1887 — 50 years before Volkswagen Aktiengesellschaft, which was founded in 1937. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Volkswagen Aktiengesellschaft.
How many employees does Bristol-Myers Squibb Company have compared to Volkswagen Aktiengesellschaft?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Volkswagen Aktiengesellschaft employs approximately 663,000. Volkswagen Aktiengesellschaft has the larger workforce at 663,000 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Volkswagen Aktiengesellschaft headquartered?
Bristol-Myers Squibb Company is headquartered in United States and Volkswagen Aktiengesellschaft is headquartered in Germany. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Bristol-Myers Squibb Company and Volkswagen Aktiengesellschaft?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Volkswagen Aktiengesellschaft was founded by Ferdinand Porsche.
Which company has a longer operating history — Bristol-Myers Squibb Company or Volkswagen Aktiengesellschaft?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Volkswagen Aktiengesellschaft has been in operation for around 89 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs Volkswagen overview